GCTK Glucotrack, Inc.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1506983 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY40.4%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-620.6%
ROA-272.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets216.5%
Debt / equity—
Current ratio0.46x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio4.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.02M | $2.13M | $1.63M | $3.17M | $3.15M | $1.87M | $1.70M | $2.06M |
| SG&A expense | $1.38M | $2.07M | $2.29M | $1.02M | $1.65M | $1.63M | $2.06M | $1.06M |
| Operating income | -$3.40M | -$4.20M | -$3.49M | -$4.31M | -$4.80M | -$3.50M | -$3.85M | -$3.25M |
| Interest expense | — | — | — | — | — | — | $39,000 | $5,000 |
| Net income | -$3.81M | -$4.33M | -$3.63M | -$4.17M | -$4.76M | -$6.83M | -$10.09M | -$5.09M |
| EBITDA | -$3.38M | -$4.18M | -$3.47M | -$4.30M | -$4.79M | -$3.49M | -$3.84M | -$3.24M |
| EPS (basic) | 0.76 | 2.65 | — | 4.64 | 9.62 | 40.14 | — | 1,092.00 |
| EPS (diluted) | 0.76 | 2.65 | — | 4.64 | 9.62 | 40.14 | — | 1,092.00 |
| Weighted avg. shares (diluted) | 5.01M | 1.64M | — | 899,410 | 494,504 | 169,345 | — | 4,663 |
| Balance sheet | ||||||||
| Cash & equivalents | $1.12M | $3.93M | $7.38M | $7.87M | $9.55M | $9.10M | $5.62M | $346,000 |
| Current assets | $1.38M | $4.21M | $7.67M | $8.11M | $10.08M | $9.46M | $5.77M | $642,000 |
| PP&E, net | $95,000 | $116,000 | $138,000 | $144,000 | $87,000 | $94,000 | $95,000 | $109,000 |
| Total assets | $1.50M | $4.36M | $7.84M | $8.29M | $10.21M | $9.61M | $5.93M | $826,000 |
| Current liabilities | $2.99M | $4.97M | $4.77M | $5.30M | $3.08M | $1.95M | $1.27M | $4.61M |
| Total liabilities | $3.24M | $5.21M | $5.01M | $5.54M | $3.33M | $2.35M | $18.93M | $4.85M |
| Shareholders' equity | -$1.74M | -$851,000 | $2.83M | $2.75M | $6.88M | $7.26M | -$13.00M | -$4.02M |
| Shares outstanding | 6.26M | 2.52M | 910,688 | 899,410 | 899,410 | 25.59M | 13,409 | 5.77M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.62M | -$4.05M | -$3.94M | -$4.62M | -$3.74M | -$2.94M | -$3.50M | -$4.14M |
| Capital expenditure | — | — | $20,000 | $67,000 | $0 | $9,000 | $0 | $33,000 |
| Free cash flow | — | — | -$3.96M | -$4.69M | -$3.74M | -$2.95M | -$3.50M | -$4.17M |
| Investing cash flow | — | — | -$20,000 | -$67,000 | $0 | -$9,000 | $0 | -$33,000 |
| Financing cash flow | $803,000 | $591,000 | $3.49M | $2.99M | $4.16M | $6.39M | $8.78M | $4.38M |
| Depreciation & amortization | $21,000 | $22,000 | $14,000 | $9,000 | $11,000 | $8,000 | $14,000 | $10,000 |
| Stock-based compensation | $59,000 | $61,000 | $90,000 | $41,000 | $40,000 | $40,000 | -$66,000 | $11,000 |
Free plan shows the latest 8 periods; Pro shows all 64 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.